X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA DR. DATSONS LABS ALEMBIC PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 28.3 -10.9 - View Chart
P/BV x 6.4 0.2 3,971.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALEMBIC PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
DR. DATSONS LABS
Mar-14
ALEMBIC PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs792126 630.3%   
Low Rs44331 1,433.7%   
Sales per share (Unadj.) Rs167.0133.0 125.6%  
Earnings per share (Unadj.) Rs38.20.2 25,171.0%  
Cash flow per share (Unadj.) Rs42.06.6 635.5%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.9128.8 65.9%  
Shares outstanding (eoy) m188.5231.66 595.5%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x3.70.6 628.2%   
Avg P/E ratio x16.2516.1 3.1%  
P/CF ratio (eoy) x14.711.8 124.1%  
Price / Book Value ratio x7.30.6 1,196.8%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3832,477 4,697.8%   
No. of employees `000NANA-   
Total wages/salary Rs m4,21456 7,524.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m31,4874,211 747.8%  
Other income Rs m5579 70.0%   
Total revenues Rs m31,5424,289 735.4%   
Gross profit Rs m10,060569 1,769.2%  
Depreciation Rs m722204 353.3%   
Interest Rs m37430 8.6%   
Profit before tax Rs m9,35613 73,669.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2-2 83.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1606 35,413.1%   
Profit after tax Rs m7,1945 149,881.3%  
Gross profit margin %31.913.5 236.6%  
Effective tax rate %23.148.0 48.1%   
Net profit margin %22.80.1 20,042.3%  
BALANCE SHEET DATA
Current assets Rs m15,0666,852 219.9%   
Current liabilities Rs m7,6746,711 114.4%   
Net working cap to sales %23.53.3 701.0%  
Current ratio x2.01.0 192.3%  
Inventory Days Days67161 41.6%  
Debtors Days Days41318 12.8%  
Net fixed assets Rs m8,2373,673 224.3%   
Share capital Rs m377317 119.1%   
"Free" reserves Rs m15,4163,761 409.9%   
Net worth Rs m16,0054,078 392.5%   
Long term debt Rs m01,671 0.0%   
Total assets Rs m24,59412,633 194.7%  
Interest coverage x255.21.0 24,792.0%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.30.3 384.1%   
Return on assets %29.43.4 853.9%  
Return on equity %44.90.1 38,183.4%  
Return on capital %58.77.7 764.6%  
Exports to sales %55.722.9 243.5%   
Imports to sales %10.414.3 72.9%   
Exports (fob) Rs m17,551964 1,820.6%   
Imports (cif) Rs m3,283602 545.4%   
Fx inflow Rs m17,811964 1,847.6%   
Fx outflow Rs m5,318607 876.0%   
Net fx Rs m12,493357 3,500.3%   
CASH FLOW
From Operations Rs m9,3041,345 691.8%  
From Investments Rs m-3,105-2,256 137.6%  
From Financial Activity Rs m-1,959-1,200 163.3%  
Net Cashflow Rs m4,240-2,111 -200.9%  

Share Holding

Indian Promoters % 74.1 4.5 1,635.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.0 -  
FIIs % 9.1 1.4 674.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 94.1 14.8%  
Shareholders   49,328 20,807 237.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  ORCHID PHARMA LTD  PFIZER  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Hits 36,000-Mark; Infosys & Tata Steel Top Gainers(09:30 am)

Asian equities are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.82% while the Hang Seng is up 1.26%. The Nikkei 225 is trading up by 0.93%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 23, 2018 11:09 AM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS